Coronary Artery Disease Clinical Trial
— Gladius FirstOfficial title:
Coronary Chronic Total Occlusion Percutaneous Coronary Intervention Using Antegrade Wiring Strategy With a First-choice Gladius Guidewire: a Randomized Clinical Study (Gladius First Trial)
The Gladius First trial is designed as a single-centre, open, prospective, randomized clinical trial aimed to assess the efficiency and safety of coronary chronic total occlusion (CTO) percutaneous coronary intervention (PCI) using the antegrade wiring strategy with a first-choice intermediate Gladius guidewire. To this end, consecutive patients referred to CTO PCI with intended primary antegrade wire escalation strategy, will be randomized in a 1:1 fashion to antegrade wiring starting with the Gladius guidewire or antegrade wiring using the standard guidewire escalation strategy.
Status | Recruiting |
Enrollment | 70 |
Est. completion date | May 1, 2024 |
Est. primary completion date | January 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - delivery of an informed consent and compliance with study protocol - CTO of a major coronary artery with at least intermediate difficulty score (J-CTO =1) as assessed by invasive angiography - referral to clinically indicated CTO PCI with intended primary antegrade wiring strategy Exclusion Criteria: - in-stent CTO - unstable angina and/or myocardial infarction - prior myocardial infarction within 4 weeks before study enrolment - CTO of a major coronary artery with an easy difficulty score (J-CTO 0) as assessed by invasive coronary angiography - lack of valid antegrade wire escalation strategy as assessed by 2 independent CTO PCI operators - chronic kidney disease (defined as eGFR =30 ml/min/m2) - contraindication to antiplatelet therapy and/or heparin - severe inflammatory disease - positive pregnancy test or breast-feeding |
Country | Name | City | State |
---|---|---|---|
Poland | National Institute of Cardiology | Warsaw |
Lead Sponsor | Collaborator |
---|---|
National Institute of Cardiology, Warsaw, Poland |
Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | time-efficiency of antegrade wiring strategy | time-efficiency of antegrade wiring strategy defined as the time from advancement of the first wire into the proximal cap to either the time of successful antegrade wiring through the lesion or the time of cessation of antegrade wiring and changing CTO PCI strategy according to the hybrid algorithm | during procedure (intraprocedural) | |
Secondary | time-efficiency of successful antegrade wiring strategy | time-efficiency of successful antegrade wiring strategy defined as the time from advancement of the first wire into the proximal cap to the time of successful antegrade wiring through the lesion | during procedure (intraprocedural) | |
Secondary | time-efficiency of successful antegrade approach | time-efficiency of successful antegrade approach defined as the time from advancement of the first wire into the proximal cap to either the time of successful antegrade wiring through the lesion or successful antegrade dissection and re-entry strategy | during procedure (intraprocedural) | |
Secondary | time-efficiency of antegrade approach | time-efficiency of antegrade approach defined as the time from advancement of the first wire into the proximal cap to either the time of successful antegrade wiring or antegrade dissection and re-entry strategy or the time of failed antegrade approach and changing CTO PCI strategy according to the hybrid algorithm | during procedure (intraprocedural) | |
Secondary | time-efficiency of successful CTO recanalization using any technique | time-efficiency defined as the time from advancement of the first wire into the proximal cap to the time of successful CTO recanalization using any technique (including antegrade and retrograde strategies) | during procedure (intraprocedural) | |
Secondary | total procedural time | total procedural time defined as the time from getting arterial access to the time of removal of the arterial sheaths | during procedure (intraprocedural) | |
Secondary | successful guidewire crossing through CTO using antegrade wiring strategy | successful guidewire crossing through CTO using antegrade wiring strategy | during procedure (intraprocedural) | |
Secondary | successful guidewire crossing through CTO with restoration of flow using antegrade wiring strategy | successful guidewire crossing through CTO with restoration of flow (<50% residual stenosis and TIMI flow grade 3) using antegrade wiring strategy | during procedure (intraprocedural) | |
Secondary | successful guidewire crossing through CTO using antegrade approach (including antegrade wiring and antegrade dissection and re-entry strategies) | successful guidewire crossing through CTO using antegrade approach (including antegrade wiring and antegrade dissection and re-entry strategies) | during procedure (intraprocedural) | |
Secondary | successful guidewire crossing through CTO with restoration of flow using antegrade approach (including antegrade wiring and antegrade dissection and re-entry strategies) | successful guidewire crossing through CTO with restoration of flow (<50% residual stenosis and TIMI flow grade 3) using antegrade approach (including antegrade wiring and antegrade dissection and re-entry strategies) | during procedure (intraprocedural) | |
Secondary | final procedural success defined as successful guidewire crossing through CTO with restoration of flow | final procedural success defined as successful guidewire crossing through CTO with restoration of flow (<50% residual stenosis and TIMI flow grade 3) | during procedure (intraprocedural) | |
Secondary | contrast volume related to successful guidewire crossing through CTO using antegrade wiring strategy | contrast volume related to successful guidewire crossing through CTO using antegrade wiring strategy | during procedure (intraprocedural) | |
Secondary | total contrast volume | total contrast volume | during procedure (intraprocedural) | |
Secondary | radiation dose related to successful guidewire crossing through CTO using antegrade wiring strategy | radiation dose related to successful guidewire crossing through CTO using antegrade wiring strategy | during procedure (intraprocedural) | |
Secondary | total radiation dose | total radiation dose | during procedure (intraprocedural) | |
Secondary | incidence of periprocedural complications | incidence of periprocedural complications defined as: coronary perforation, tamponade, life-threatening arrhythmia requiring treatment, transient ischemic attack, stroke, myocardial infarction, urgent cardiac surgery, death | during hospitalization (assessed up to 30 days) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
|
N/A |